BRCA2 and cancer: Li et al. identified several RAD52 inhibitors through virtual HTS and docking studies with top compounds F779-0434 and C791-0064 inhibiting RAD52-ssDNA association and disrupting single strand annealing activity of RAD52, respectively and inducing synthetic lethality by suppressing the proliferation of BRCA2-deficient cancer cells at high concentrations (190, 191).